| CTGA | complete transposition of great arteries |
|---|---|
| FCA | ferritin-conjugated antibodies; Freund's complete adjuvant; functional capacity assessment |
| MCC | mean corpuscular hemoglobin concentration; medial cell column; Medical Council of Canada; metacerebr... |
| ROM | CP range of motion complete and painfree |
| tG1 | the time required to complete the G1 phase of the cell cycle |
| calcium aminosalicylate | The calcium salt of p-aminosalicylic acid, with the same uses. (05 Mar 2000) |
|---|---|
| calcium antagonist | calcium channel-blocking agent |
| calcium ATPase | <enzyme> Usually used of the calcium pumping ATPase present in high concentration as an integral membrane protein of the sarcoplasmic reticulum of muscle. This pump lowers the cytoplasmic calcium level and causes contraction to stop. Normal function of the pump seems to require a local phospholipid environment from which cholesterol is excluded. (18 Nov 1997) |
| calcium benzoylpas | Calcium 4-benzamidosalicylate;an antituberculous agent. (05 Mar 2000) |
| calcium-binding protein | <biochemistry> There are two main groups of calcium binding proteins, those that are similar to calmodulin and are called EF hand proteins and those that bind calcium and phospholipid (e.g. Lipocortin) and that have been grouped under the generic name of annexins. Many other proteins will bind calcium, although the binding site usually has considerable homology with the calcium-binding domains of calmodulin. They can act as transport proteins, regulator proteins or activator proteins. There is also a vitamin D-dependent variant which is a protein that plays a fundamental role in the vitamin d mediated transport of calcium in reptiles, amphibians, birds and mammals. It is found in the intestine, kidneys, egg shell gland, brain, and possibly other organs. Its molecular weight is species dependent. (12 May 2002) |
| calcium bromide | Used to meet the same indications as potassium bromide. (05 Mar 2000) |
| calcium-calmodulin-activated histone 3 arginine kinase | <enzyme> From nuclear extracts of dividing and quiescent rat heart endothelial cells; represents a new class of ca-cam-dependent kinases which phosphorylate arg Registry number: EC 2.7.10.- Synonym: ca(2+)-calmodulin-activated histone 3 arg kinase, ca-cam h3 kinase (26 Jun 1999) |
| calcium-calmodulin-dependent phosphodiesterase | <enzyme> Hydrolyzes both cgmp and camp; induced during mitogenesis Registry number: EC 3.1.4.- Synonym: ca-cam-phosphodiesterase, calmodulin-dependent cgmp phosphodiesterase (26 Jun 1999) |
| calcium-calmodulin dependent protein kinase | <enzyme> A calmodulin-dependent enzyme that catalyses the phosphorylation of proteins. This enzyme is also sometimes dependent on calcium. A wide range of proteins can act as acceptor, including vimentin, synapsin, glycogen synthase, myosin light chains, and the microtubule-associated proteins. Registry number: EC 2.7.10.- (12 Dec 1998) |
| calcium carbide | CaC2;blackish crystalline lumps which when in contact with water yield acetylene gas. (05 Mar 2000) |
| calcium carbimide | <drug> This drug is used to treat alcoholism, if a person takes this drug and then drinks any alcohol at all, they will get sick (headache, nausea, vertigo, etc.) (09 Oct 1997) |
| calcium carbonate | An astringent, an antacid (27 Sep 1997) |
| calcium caseinate | The form of casein present in cow's milk; used in dietetic preparations; has been used for diarrhoea in infants. (05 Mar 2000) |
| calcium channel | <physiology> A membrane channel that is specific for calcium. It is a voltage-dependent cell membrane glycoproteins selectively permeable to calcium ions. They are categorised as l, t, n, or p types based on the activation and inactivation kinetics, ion specificity, and sensitivity to drugs and toxins. (12 May 2002) |
| calcium channel agonist | <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. (12 Dec 1998) |